ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

INCA036978

A development code.

Its studies are mostly in Myeloproliferative Disorders, led by Incyte.

Furthest: phase 1, since Feb 13, 20261 company-led study, 1 open or runningNext primary completion: May 24, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte11 open or runningphase 1since Feb 13, 2026Feb 13, 2026May 24, 2030phase 1 · NCT07441694

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2026First study: phase 1 study in Myeloproliferative DisordersFirst studyNCT07441694 · 218 planned · United States, Australia, Belgium and more

Ahead

  1. May 24, 2030Primary completion: phase 1 study in Myeloproliferative DisordersNCT07441694

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07441694Myeloproliferative Disorders · United States, Australia, Belgium and more1RecruitingMay 24, 2030218

How it is read

Names in the registry

  • “INCA036978”, 1 entry

Codes read as this program: INCA036978.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.